AbstRAct
chronologically scored by one experienced reader who was unaware of genetic or clinical data using the Sharp-van der Heijde scoring method (SHS). The correlation coefficient (ICC) within the reader was 0.91. Treatment strategies differed in three treatment periods:
(1993-1995, initial treatment with NSAIDs, 1996-1998, initial treatment with chloroquine or salazopyrine and 1999-2006 prompt treatment with methotrexate or sulfasalazine). 1 
Phase-2
Here, 686 North American 1987-ACR-criteria-positive RA-patients were studied. 118
were recruited from a practice in Wichita 14 , Kansas and 568 were recruited from the National Databank of Rheumatic Diseases (NDB). 15 Serial hands X-rays were available in the patients recruited from Wichita. In the NDB-patients, hands X-rays were made at a single time-point. All X-rays were SHS-scored by one experienced reader (ICC=0.98). All patients developed RA in eras when early, tailored treatment and use of biologics were uncommon.
16
Patients gave informed consent. Approval was obtained from the local medical ethical committees.
Genotyping

Phase-1
Genotyping was done using the Immunochip according to Illumina's protocols. 9 The Illumina Genome Studio software was used to perform the SNP clustering. The SNP clustering and quality control of samples was performed as described in Trynka et al. 9 Samples were excluded for call rate <99.5% across 172,242 markers. We also excluded samples for incompatible recorded and genotype-inferred gender, duplicates and first-or second-degree relatives. Potential ethnic outliers were identified by multi-dimensional scaling plots of samples merged with HapMap3 data.
Initially, 704 RA cases were genotyped. 14 patients were excluded due to call rates below 99.5%, 16 because they were relatives or duplicates, 26 because they were population outliers and 1 patient was excluded because of a gender mismatch. Finally, one patient was excluded because no clinical data were available. After quality control 646
Dutch RA cases were included in the analysis. After removing non-polymorphic markers, 148,880 SNPs remained for further analysis. In this study SNPs with MAF>0.01 (130,841 SNPS) were analyzed.
Phase-2
Genotyping of phase-2 samples was done by Immunochip. Quality control was similar as in phase-1. SNPs that were significantly associated with the severity of joint damage in phase-1 were selected and analyzed.
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Phase-1
In both phases the radiological scores were log-transformed in order to obtain a normal
distribution. An additive model was used. SNPs can have a constant effect effect over time, an effect on progression, or both. In the present study, evaluating >100k SNPs, it
was not possible to study the raw data per SNP to chose the effect to be tested. Therefore, a method that analyzed both constant and main effects together was used, this resulted in an "overall p-value". This concerned a marginal regression model for longitudinal data with the radiological score as a response variable. This method takes advantage of the within-person correlation between repeated measurements. The null hypothesis was that the coefficients for both the main SNP effect and its interaction with time equal zero, the alternative hypothesis was that at least one differed. This hypothesis has been tested using the likelihood ratio test, which is assumed to follow under the null the chi-squared distribution with 2 degrees of freedom. The effect of time was entered as a factor in the model, to capture the mean response profile over time properly. The effect of time in the interaction term was linear. Adjustment variables (age, gender and the described treatment strategies) were entered based on their univariate association with joint destruction. The
Bonferroni correction for multiple testing was done by the number of uncorrelated SNPs.
In the phase-1, multiple testing correction was based on R 2 >0.5 (44,544 uncorrelated SNPs). Given the explorative character of this phase, that would be followed be a replication phase, we have chosen to correct for the number of SNPs with R 2 >0.5; hence the cut-off for significance was set at 1.1x10 -6 .
Phase-2
An additive model was used. In the Wichita-patients, associations between genetic variances and joint destruction over time were analyzed using a marginal regression model as described above. For the NDB-patients, the estimated yearly progression rate was calculated (total SHS divided by disease years at time of X-ray). The mean disease duration at the time of the X-ray was 10 years. The SNP association was tested in a linear regression model with log e (estimated progression+1) as outcome variable. Analyses were corrected for gender and age. All patients were included (long) before 2000, when treatment was relatively mild and treatment strategies did not change between the inclusion years.
Treatment adjustments were therefore not made. As both cohorts evaluated in phase-2 had less patients and less X-rays than the cohort of phase-1, the power was expected to be insufficient to obtain significant results in the individual cohorts. Therefore, the coefficients for the main SNP effect and its interaction with time observed in both data-sets of phase-2 were combined into an inverse variance weighted fixed-effects meta-analysis. Testing of serum-MMP-9 levels Levels of MMP-9 in the baseline serum samples of 105 patients with RA from the Leiden EAC were measured using ELISA (eBioscience BMS2016/2). Patients were selected on their genotype (homozygous major versus homozygous minor) in rs11908352, the most significantly associating SNP on chromosome 20.
Software
All analyses were done using the R statistical software package. 
REsuLts
Phase-1
The characteristics of the patients studied are presented in Table 1 . In the first phase, 109
SNPs passed the threshold for significance (P<1.1x10 -6 , Supplementary Table 1) . Of these, 76 were located in the HLA-region on chromosome 6; a region of which the association with severity of joint damage was already known. 19 These variants were not studied in *Data of Leiden-EAC for 7 of follow-up, respectively. In the Wichita and NDB patients, the maximum duration of follow-up was 15 and 20 years respectively. EAC: Early Arthritis Clinic, SHS: Sharp-van-der-Heijde score.
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A variant in MMP-9, serum levels and joint destruction in RA phase-2. Among the other 33 non-HLA genetic variants (presented in Table 2 ), several were in high LD. A Q-Q plot of the p-value distribution is depicted in Supplementary   Figure 1 . 
Rs451066
The progression of joint destruction of the patients with different rs451066 genotypes is presented in Figure 1 
Rs11908352
The raw SHS-scores of patients with different rs11908352 genotypes are presented in and rs4810485 showed an independent association for rs11908352 (p=0.006) with RA severity. Rs11908352 is located 25 kb at the 3'end of the gene encoding for MMP-9 and in high LD with some variants located within the MMP-9 gene (see Figure 2D for fine mapping results). Several variants within the MMP-9 gene showed association to RA-severity, however, in a conditional analysis including these variants, only rs11908352 yielded a significant result (p=0.035). Altogether, we observed that rs11908352 was the strongest with progression of joint damage associating SNP in this region.
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MMP-9 serum levels
Subsequently, we tested whether the different genotypes of rs11908352 were related to different serum levels of MMP-9 using a linear regression analysis. Patients carrying the AA genotype, which was also associated with more severe joint damage, had significantly higher serum levels of MMP-9 compared to patients carrying the CC (major) allele combination (p=0.007, see Figure 2C ). In order to evaluate whether the effect was independent of markers of systemic inflammation, this analysis was repeated with the log-transformed CRP values at baseline as a covariate. Patients carrying the AA genotype still had significantly higher serum levels of MMP-9 (p=0.008). 
Subanalyses
With regards to RA susceptibility it has been observed that some genetic variants predispose only to ACPA-positive or ACPA-negative disease. In line with this it can be questioned whether genetic factors associating with joint damage progression are also different for ACPA-positive and ACPA-negative RA. 20 It was observed that for rs451066 the effect sizes were almost similar in both subgroups; for rs11908352 the effect size was larger in the ACPA-positive than in the ACPA-negative subgroup. However, considering the small number of patients per subgroup, none of these analyses resulted in significant p-values.
Larger studies are required for definite conclusions on the differential association of these variants in ACPA-positive and ACPA-negative RA. Figure  2C , MMP-9 serum levels in patients of phase-1 carrying rs11908352 AA and CC genotype are depicted. The mean serum level for the patients carrying the AA alleles was 1493ng/ml, whereas the mean level for the patients carrying the CC alleles was 1112ng/ml. In Figure 2D , the p-values of the SNPs of the region form 44027635 to 44217743 Kb on chromosome 20, their linkage and the genes located in this region are depicted. Rs6073985 was, after rs11908352 and rs62215576 the next best hit in this region (p=2.26x10 -6
; the R 2 between rs11908352 and rs6073985 was 0.38).
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A variant in MMP-9, serum levels and joint destruction in RA discussion The present study aimed to identify the genetic variants that associate with progression of joint destruction in RA. Associated genetic risk factors, and therefore presumably also part of the underlying pathogenesis, are shared in several auto-immune diseases. Furthermore, genetic variants that confer risk to disease development may also affect disease progression. These estimations prompted us to evaluate associations between genetic risk factors for a wide range of auto-immune diseases and the severity of the radiographic joint destruction in RA. The present study identified and provided independent replication for two new genetic risk variants for the severity of joint damage in RA and an association with the protein expression for one of these two variants.
Rs11908352 was observed to be associated with the severity of joint damage in RA. This variant is located on chromosome 20, in a region also encompassing rs4810485 (CD40) that is associated with susceptibility to RA. In a previous study, we reported an association between this SNP and the severity of joint destruction.
4 Rs11908352 is however in low LD (R 2 0.062) with rs4810485 on CD40 and the finding observed here is independent of this variant in CD40. Rs11908352 is located at the 3'site of MMP-9 and in high LD with SNPs located within MMP-9. MMP-9 is a member of a group of secreted zinc metalloproteinases which degrade the collagens of the extracellular matrix. MMP-9 is, amongst others, produced by macrophages and increased serum levels of MMP-9 have been described in RA. 21 Expression of MMP-9 has also been demonstrated in fibroblasts and osteoblast-like cells in the subchondral bone of destructive joints in RA. 20 We subsequently explored how this genetic variant could affect progression and questioned whether rs11908352 influences joint destruction by a mechanism that also influences the serum levels of MMP-9.
We observed that patients with the AA genotype that was associated with more severe joint damage also had higher serum levels of MMP-9. This may suggest that rs11908352 affects MMP-9 production.
Interestingly, the rs11908352 variant is located in the region active chromatin, as indicated by the recent findings of Encyclopedia of DNA Project (ENCODE). 22 In the majority of cell types (127 out of 148) included to the ENCODE project, the locus containing rs11908352 is annotated to be in the DNAse hypersensitive site (DHS). DHS sites are enriched for regulatory and promoters regions and is a sign of active genome locus. Moreover, the rs11908352 C/A variant itself alters the regulatory motifs of EVI-1 and HBP1, according to the HaploReg database. 23 Both are the transcriptional regulators that bind to DNA sequence in the promoter regions of target genes and regulate their expression. This can possibly explain the mechanism of the effect of the rs11908352 genotype on MMP-9 transcription. Rs11908352 was not annotated as an eQTL.
The other SNP that was identified in both phases was rs451066. The region of rs451066 was previously shown to be associated with susceptibility to type-1 diabetes. 24 A conditional analysis revealed that the association between rs451066 and joint destruction is independent of the effect of rs1465788, the SNP linked to type-1 diabetes susceptibility.
Nonetheless, the present data may imply that type-1 diabetes and progression of RA have a partly shared genetic background.
Interestingly, the variants observed here were not identified as risk factors for the development of RA in the Immunochip study of Eyre et al. 11 In addition, Eyre et al identified genetic risk factors for RA susceptibility that did not appear in the top list of SNPs of the present study. The p-values of the association between the known RA susceptibility factors and the severity of joint damage in phase-1 are presented in Supplementary Table 2 .
IL-2RA was identified as risk factor for RA development and joint damage progression in previous studies. 11;13 TNFAIP3-OLIG3 was identified but not replicated as severity factor. 25 The other variants that achieved nominal significance were not yet studied in independent cohorts. It should be noted that the present study contained considerably less patients than the study of Eyre et al. Nonetheless these data indicate that the genetic factors associated with susceptibility to and progression of RA are mostly different, suggesting that the processes driving the development of RA and progression of joint damage within RA are different as well.
Strengths of this study include the evaluation of RA-patients with serial X-rays; the presence of repeated radiological measurements increases the reliability with which the outcome measure can be determined, and hence increases the power. Clinical data were collected in eras when treatment was less aggressive than today and biologics were not yet common. Hence the natural course of the patients studied was less inhibited than that of patients that are currently being treated. The patients included in the Leiden EAC were treated conventionally, though with different strategies and adjustments for these differences were made. The US patients were included in even earlier time periods and no treatment effects were observed. Another strength of the study is that the identified loci were densely genotyped by the Immunochip allowing detection of the genetic variant in the region that has the strongest association.
The approach taken also encompasses several disadvantages. In contrast to conventional GWAS, the Immunochip only covers pre-selected regions on the genome. Therefore, our study-design is not suitable for detecting associations between genomic regions not included on this chip. Furthermore, the present study may include false-negative findings.
This is inherent to a study design in which a lot of variants are genotyped and analyzed.
In addition, although our study included a considerable number of patients and X-rays, achieving adequate power in longitudinal cohort studies remains difficult as high-quality long-term outcome data are required. Hence the approach is focused on finding replication of the most significant signals, we can therefore not exclude that other SNPs located on the Immunochip platform, that had p-values higher than 1.1x10 -6 in phase-1 could be associated with the rate of joint destruction in RA.
In conclusion, the current data indicate that two loci that confer risk to autoimmune disease may specifically affect the severity of joint destruction in RA, and one of these effects is mediated by a mechanism that also affects MMP-9 serum levels. Further studies are required to unravel the functional consequences of carrying these risk factors, and the processes mediating radiographic progression in RA.
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